These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18354433)

  • 21. Boxed Warning Removed from Canagliflozin Labeling.
    Aschenbrenner DS
    Am J Nurs; 2020 Dec; 120(12):22. PubMed ID: 33214366
    [No Abstract]   [Full Text] [Related]  

  • 22. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How the FDA can overturn Wyeth v. Levine.
    Gostanian A
    Am J Law Med; 2010; 36(1):248-68. PubMed ID: 20481407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of pharmacoeconomics and outcomes research.
    Radensky P
    Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

  • 26. Science and the Supreme Court: Cases to watch in 2018.
    Reardon S
    Nature; 2018 Oct; 562(7726):175. PubMed ID: 30301986
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA off-track on off-label drug promotion.
    Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmaceutical promotion and First Amendment rights.
    Troy DE; Gottlieb S
    N Engl J Med; 2008 Jul; 359(5):536; author reply 536-7. PubMed ID: 18669437
    [No Abstract]   [Full Text] [Related]  

  • 29. Judge strikes down FDA policies on industry dissemination of off-label information.
    Miller JL
    Am J Health Syst Pharm; 1999 Sep; 56(17):1695-6. PubMed ID: 10512492
    [No Abstract]   [Full Text] [Related]  

  • 30. Court rules generic drug companies not responsible for adverse outcomes.
    Kouros N
    Monash Bioeth Rev; 2013 Sep; 31(2):23-4. PubMed ID: 24844072
    [No Abstract]   [Full Text] [Related]  

  • 31. Trying times for generic medicines in the USA.
    Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540840
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 33. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
    [No Abstract]   [Full Text] [Related]  

  • 34. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 35. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 36. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceutical promotion to physicians and First Amendment rights.
    Kesselheim AS; Avorn J
    N Engl J Med; 2008 Apr; 358(16):1727-32. PubMed ID: 18420505
    [No Abstract]   [Full Text] [Related]  

  • 38. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 39. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 40. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.